<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830241</url>
  </required_header>
  <id_info>
    <org_study_id>HYPOTONIA</org_study_id>
    <nct_id>NCT04830241</nct_id>
  </id_info>
  <brief_title>Neonatal Hypotonia Associated With in Utero Exposure to Antidepressant</brief_title>
  <official_title>Neonatal Hypotonia Associated With in Utero Exposure to Antidepressant-Analysis of Two Pharmacovigilance Databases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To better characterize the neonatal hypotonia associated with in utero exposure to&#xD;
      antidepressants, so far limited to clinical cases, we will perform an observational&#xD;
      retrospective pharmacovigilance study, using two databases. First, disproportionality&#xD;
      analysis in VigibaseÂ®, the World Health Organization global database, will be perform between&#xD;
      antidepressant drugs and neonatal hypotonia . Second, narratives from the French National&#xD;
      Pharmacovigilance Database will be extracted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>neonatal hypotonia</measure>
    <time_frame>Case reported in the World Health Organization (WHO) pharmacovigilance database to April 1st 2021</time_frame>
    <description>Identification and extractions of cases of neonatal hypotonia newborns following in utero exposure to antidepressant drugs</description>
  </primary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Neonatal Hypotonia</condition>
  <condition>Antidepressant Drug Adverse Reaction</condition>
  <condition>Pregnancy Related</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressant</intervention_name>
    <description>Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity</description>
    <other_name>in utero exposure to antidepressant drugs</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all neonatal hypotonia newborns cases associated with in utero exposure to antidepressant&#xD;
        drugs retrived in the two pharmacovigilance database&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  neonatal hypotonia newborns cases associated with in utero exposure to antidepressant&#xD;
             drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reports with maternal suicide, congenital malformation and hypotonia occurring only&#xD;
             during breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <state>Normandy</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Hypotonia</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

